Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.
The FDA approved isatuximab-irfc for use in combination with carfilzomib and dexamethasone for the treatment of adults with relapsed refractory multiple myeloma (RRMM) who previously received 1 to 3 prior lines of therapy.
Sarclisa, from Sanofi-Aventis, is already approved in combination with pomalidomide and dexamethasone for the same indication. Carfilzomib (Kyprolis) is sold by Amgen; carfilzomib and dexamethasone is known as Kd therapy.
Multiple myeloma is the second most common blood cancer, affecting more than 130,000 US patients.
Sanofi said the approval is based on data from the phase 3 IKEMA study, a randomized, multicenter, open label clinical trial that enrolled 302 patients. The group was considered difficult-to-treat due to advanced age, high cytogenetic risk, or kidney disease.
Isatuximab added to Kd reduced the risk of disease progression or death by 45% (HR, 0.548; 95% CI, 0.366-0.822; P = .0032) versus standard of care Kd alone.
However, the median progression-free survival (PFS) for the triple therapy was not reached at the time of the pre-planned interim analysis, compared with 20.27 months for those given Kd (HR = 0.548; 95% CI, 0.366-0.822). OS data were immature at the time of the interim analysis.
Overall response rate did not differ significantly between the isatuximab-irfc combination and control groups (86.6% vs. 82.9%), with complete response rates of 39.7% vs. 27.6%.
The most common adverse events associated with the combination therapy included upper respiratory tract infection, infusion-related reactions, fatigue, hypertension, diarrhea, pneumonia, dyspnea, insomnia, bronchitis, cough and back pain. Hematology laboratory abnormalities that occurred among more than 80% of treated patients included decreases in hemoglobin, lymphocytes and platelets.
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More
Interactive mHealth App Helped Improve Patients’ Lifestyle Habits After Undergoing PCI
April 29th 2024These lifestyle improvements included adherence to the Mediterranean diet, improved frequency of healthy food consumption, increased physical activity, and quitting smoking, among other factors.
Read More
UK Study: Most Patients With MG Require Hospitalization, Driving Health Care Resource Use
April 27th 2024Over a median follow-up time of nearly 3 years, three-fourths (72.8%) of patients with myasthenia gravis (MG) were hospitalized and half visited the accident and emergency department.
Read More